SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children. This landmark decision is driving widespread community discussion about its de-risking impact, significant revenue potential, and possible short squeeze, with many speculating on substantial price targets and a potential buyout by a larger pharmaceutical entity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its high-speed, compliance-first Layer 1 infrastructure, which boasts impressive transaction throughput. The community is actively discussing its potential as a "financial plumbing" solution for institutions, especially with its integration of a fiat anchor from Bridge (a Stripe company) now operational. Many view KTA as an undervalued asset for cross-chain settlement and regulated financial flows, positioning it as a compelling complementary play to established crypto and tech giants.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending after federal regulators approved an emergency permit and granted interstate status for its Santa Ynez Pipeline System, shifting regulatory authority from California to federal oversight. This is widely seen as a game-changing event that could enable the company to finally move stored oil and potentially trigger a short squeeze. However, some investors remain cautious about possible state-level legal challenges or the potential for future equity offerings.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

YEE Crypto is experiencing a surge in attention, driven by a fiercely loyal community actively buying dips and declaring it a generational opportunity within the Ethereum ecosystem. The conversation centers on an unfolding 'prophecy,' strong bullish momentum, and comparisons to legendary meme coins, positioning YEE as a potential catalyst for significant growth.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is trending amid widespread community accusations of being a "scam" or "rugpull," with many investors expressing deep frustration over its recent performance. Sentiment is heavily bearish, with calls to sell and shift assets to other cryptocurrencies like XRP, though a smaller group sees current price levels as an opportune time for accumulation ahead of a potential rebound.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently seeing a surge in conversation and trading volume following reports of significant insider stock purchases, notably by Apple CEO and Nike board member Tim Cook. This move has ignited fervent debate among the community, with many interpreting it as a strong vote of confidence and a potential turning point for the struggling brand, while skeptics question its fundamental impact amidst ongoing performance concerns.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to promising preliminary Phase 3 open-label data indicating a significant reduction in breast cancer recurrence rates. The community is actively discussing the very high cost-to-borrow rates and a low share float, fueling strong short-squeeze speculation. This is compounded by significant insider buying from the CEO, leading to widespread anticipation of a major partnership or acquisition within the biotech sector.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a top trending stock after securing FDA approval for its oral Wegovy pill, marking a significant milestone as the first GLP-1 oral therapy for weight management. The community is buzzing with excitement over the convenience of a pill versus injections, anticipating a massive expansion of the obesity market and a competitive edge against rivals. Investors are looking for a substantial re-rating of the stock, believing this approval signals a new era of growth and market leadership.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by positive regulatory developments, strategic divestitures, and key partnerships in wealth management and digital payments. This rally has sparked extensive community discussion, with many celebrating its strong performance and ongoing transformation plan, while others express caution due to its rapid ascent and overbought technical indicators. The positive sentiment is reinforced by strong earnings and analyst upgrades, positioning it as a notable performer within the broader financial sector.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is seeing heightened conversation following a recent US$20 million public offering aimed at funding its demonstration-scale plant. Enthusiastic investors highlight the company's graduation from Shell's GameChanger program and new partnerships as strong validation for its unique recycling technology, while skeptics warn of a "pump and dump" lacking revenue and view the valuation as unsustainable.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Buys Global Rights To Preclinical Cancer Therapy For $357M

In preclinical studies, the ADC was effective at shrinking tumors without causing a proportional increase in significant side effects, even at higher doses, GSK said. 

Equity

The National Highway Traffic Safety Administration (NHTSA) announced on Monday that it has closed its investigation into approximately 24,000 model year 2017-2018 Alfa Romeo Giulia vehicles.The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures in certain Alfa Romeo Giulia vehicles. During its investigation, the NHTSA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24003-86036.pdf">determined</a> that the vehicles were equipped with fuel delivery pumps supplied by Vitesco Technologies Germany GmbH.However, Stellantis issued a recall earlier this month covering 29,467 model-year 2017–2019 Alfa Romeo Giulia vehicles and 24,382 model-year 2018 Alfa Romeo Stelvio vehicles, all equipped with the suspect Vitesco fuel delivery pump. A remedy is under development, the company said.The NHTSA stated that it is closing its probe in light of the recall issued by Stellantis. However, the regulator said it reserves the right to take additional action if warranted.The NHTSA also noted that it is aware of 1,900 vehicles experiencing failures related to the issue, adding that it is aware of one crash associated with the issue, but no injuries, fatalities, or fires.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> remained within ‘bearish’ territory while message volume remained at ‘high’ levels.The NHTSA also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24006-86034.pdf">announced </a>on Monday that it has closed a probe into 226,250 model year 2018-2020 Dodge Journey vehicles, which was initiated in February 2024 due to complaints regarding the backup camera function. The company recently issued a recall to resolve the issue and noted that it will replace defective cameras in the recalled vehicles with an updated part that resolves the problem.STLA stock is down 29% this year and approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Alfa Romeo Giulia on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles

The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures. 

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

Current Price	$38.85
Prev Close	$38.75
Open	$38.89
Dividend Yield	N/A
50-Day Moving Average	$37.53
Beta	N/A
Avg. Volume	1,990.89
PE Ratio	N/A

52-Week High	$39.02
52-Week Low	$30.48
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DIVD
EA Series Trust - Altrius Global Dividend ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DIVD News

DIVDEA Series Trust - Altrius Global Dividend ETF